doi.org/10.1016/s0959-8049(20)31098-4, hdl.handle.net/1765/133853
European Journal of Cancer
Erasmus MC: University Medical Center Rotterdam

Lin, C.C, Joerger, M, Grell, P., Chiappori, A.A., Leal, T.A., Kasper, S., … Tan, D.S.W. (2020). Continuous vs intermittent adenosine 2A receptor (A2AR) inhibition in preclinical colon cancer (CC) models and in a Phase (Ph) II study of taminadenant (NIR178) + spartalizumab (PDR001) in patients (pts) with non-small cell lung cancer (NSCLC). European Journal of Cancer, 138, S12–S13. doi:10.1016/s0959-8049(20)31098-4